Edition:
United Kingdom

Ophthotech Corp (OPHT.OQ)

OPHT.OQ on NASDAQ Stock Exchange Global Select Market

1.84USD
20 Nov 2018
Change (% chg)

-- (--)
Prev Close
$1.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
21,100
52-wk High
$4.49
52-wk Low
$1.82

Latest Key Developments (Source: Significant Developments)

Ophthotech Announces Results From Phase 2A Safety Trial Of Zimura In Combination With Lucentis In Wet Age-Related Macular Degeneration
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Ophthotech Corp ::OPHTHOTECH ANNOUNCES RESULTS FROM PHASE 2A SAFETY TRIAL OF ZIMURA® IN COMBINATION WITH LUCENTIS® IN WET AGE-RELATED MACULAR DEGENERATION.OPHTHOTECH CORP - ZIMURA COMBINATION THERAPY WAS GENERALLY WELL TOLERATED AFTER SIX MONTHS OF TREATMENT.OPHTHOTECH CORP - NO ADVERSE EVENTS WERE ATTRIBUTED TO ZIMURA COMBINATION THERAPY.OPHTHOTECH CORP - MOST FREQUENTLY REPORTED OCULAR ADVERSE EVENTS WERE RELATED TO INJECTION PROCEDURE.OPHTHOTECH - RESULTS FROM ITS PHASE 2A SAFETY TRIAL OF ZIMURA.  Full Article

Ophthotech Completes Patient Recruitment For Phase 2B Clinical Trial Of Zimura
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Ophthotech Corp ::OPHTHOTECH COMPLETES PATIENT RECRUITMENT AS PLANNED FOR ITS PHASE 2B CLINICAL TRIAL OF ZIMURA® MONOTHERAPY FOR GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION.OPHTHOTECH CORP - INITIAL TOP-LINE ZIMURA GEOGRAPHIC ATROPHY DATA EXPECTED IN Q4 OF 2019.OPHTHOTECH CORP - ZIMURA WET AMD DATA CONTINUES ON TRACK FOR INITIAL TOP-LINE DATA BEFORE END OF 2018.  Full Article

Ophthotech Corp Files For Mixed Shelf Of Upto $150 Mln - SEC Filing
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Ophthotech Corp ::OPHTHOTECH CORP FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Ophthotech Reports Q2 Loss Per Share $0.37
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Ophthotech Corp ::OPHTHOTECH REPORTS SECOND QUARTER 2018 FINANCIAL AND OPERATING RESULTS.Q2 LOSS PER SHARE $0.37.OPHTHOTECH - ESTIMATES YEAR-END 2018 CASH, CASH EQUIVALENTS WILL RANGE BETWEEN $112 MILLION-$117 MILLION BASED ON CURRENT 2018 BUSINESS PLAN AND PLANNED CAPEX.  Full Article

Ophthotech Enters Gene Therapy Agreements With University Of Florida And University Of Pennsylvania
Thursday, 7 Jun 2018 

June 7 (Reuters) - Ophthotech Corp ::OPHTHOTECH ENTERS INTO GENE THERAPY AGREEMENTS WITH THE UNIVERSITY OF FLORIDA AND THE UNIVERSITY OF PENNSYLVANIA.OPHTHOTECH CORP - PHASE 1/2 CLINICAL TRIAL EXPECTED TO INITIATE IN EARLY 2020.OPHTHOTECH - AS PART OF COLLABORATION, CO TO WORK IN PARTNERSHIP WITH SCIENTISTS IN GENE THERAPY FOR ORPHAN RETINAL DISEASES.  Full Article

Ophthotech Completes Patient Recruitment In A Mid-Stage Trial Of Its Eye Drug Zimura
Tuesday, 1 May 2018 

May 1 (Reuters) - Ophthotech Corp ::OPHTHOTECH COMPLETES PATIENT RECRUITMENT IN THE PHASE 2A CLINICAL TRIAL OF ZIMURA® IN COMBINATION WITH ANTI-VEGF THERAPY IN WET AGE-RELATED MACULAR DEGENERATION.OPHTHOTECH CORP - INITIAL TOP-LINE DATA EXPECTED BY END OF 2018.OPHTHOTECH CORP - WILL EVALUATE DATA AT MONTH 6.  Full Article

Ophthotech Q3 earnings per share $5.25
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Ophthotech Corp ::Ophthotech reports third quarter 2017 financial and operating results.Q3 earnings per share $5.25.Q3 earnings per share view $2.67 -- Thomson Reuters I/B/E/S.Ophthotech Corp - ‍collaboration revenue was $206.7 million for quarter ended September 30, 2017, compared to $1.7 million for same period in 2016​.Ophthotech Corp - ‍as of September 30, 2017, company had $180.2 million in cash and cash equivalents​.Ophthotech Corp - ‍expects a 2017 year end cash balance of between $155 million and $165 million​.  Full Article

Ophthotech says Fovista phase 3 trial did not meet primary endpoint
Monday, 12 Dec 2016 

Ophthotech Corp : pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal phase 3 clinical trials . addition of Fovista to monthly Lucentis regimen did not result in benefit as measured by mean change in visual acuity at 12 month time point . based on preliminary analysis of safety data, Fovista and Lucentis monotherapy were generally well tolerated after one year of treatmen .Ophthotech announces results from pivotal phase 3 trials of Fovista in wet age-related macular degeneration.  Full Article